Finding Vredo (Pat. Pending): The Dutch Supreme Court Decision on Escitalopram

Journal of Intellectual Property Law & Practice 2014, Vol. 9, No. 8, pp. 644-649

6 Pages Posted: 20 Jun 2014 Last revised: 19 Jul 2014

Multiple version iconThere are 2 versions of this paper

Date Written: February 12, 2014

Abstract

This article is about the pharma patent litigation sparked by Lundbeck’s blockbuster drug for 'escitalopram', a drug used for treating depression and generalized anxiety disorder.

The article focuses on the trials and tribulations before the Dutch Patent Court of Appeal and the Supreme Court, while also briefly contrasting and comparing this with the decisions in Germany and the United Kingdom.

Particular attention is given to novel substances that can be fully envisaged but cannot yet be made. Under the doctrine set out by the Technical Boards of Appeal, such envisaged substance can still be considered to be non-obvious and therefore patented if the claimed method for preparing such substance is the first to achieve this in an inventive manner. The Dutch Supreme Court follows this doctrine.

The author criticizes the lack of explanation provided by the Supreme Court in reversing the decision of the Court of Appeal. By merely referring to foreign precedent, the Supreme Court violates its duty to state its own reasons.

The article concludes by outlining the practical impact of the decision of the Supreme Court.

A previous version of this article also appeared in the Dutch technology law journal "BIE" and is available at: http://ssrn.com/abstract= 2406727.

Keywords: patents, patent, pharma, pharmaceutical, substance, substance protection, inventive step, non-obviousness, claim, T-595/90, escitalopram, citalopram, Lundbeck, Tiefenbacher, European Patent Convention, EPC, Tsoutsanis

JEL Classification: K06, K10, K11, K13, K19, K29, K32, K39, K40, K41, K42, K49, H51, I10, I11, I19, L12, L43, L50, L65

Suggested Citation

Tsoutsanis, Alexander, Finding Vredo (Pat. Pending): The Dutch Supreme Court Decision on Escitalopram (February 12, 2014). Journal of Intellectual Property Law & Practice 2014, Vol. 9, No. 8, pp. 644-649, Available at SSRN: https://ssrn.com/abstract=2451438

Alexander Tsoutsanis (Contact Author)

DLA Piper ( email )

Amstelveenseweg 638
Amsterdam, 1081 JJ
Netherlands

HOME PAGE: http://www.dlapiper.com/en/netherlands/people/t/tsoutsanis-alexander/

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
44
Abstract Views
781
PlumX Metrics